Antipsychotic drugs and their clinically impotent congeners were examined as inhibitors of dopamine-sensitive adenylate cyclase (EC 4.6 Phenothiazines and other structurally analogous drugs with antipsychotic action and neuroleptic drugs of the butyrophenone and diphenylpiperidine classes are reported to enhance 3,4-dihydroxyphenylethylamine (dopamine) turnover in the brain (1-4), possibly as a consequence of their blockade of dopamine receptors. This enhancement of dopamine turnover in the basal ganglia by neuroleptic agents has been suggested to be characteristic only for the subgroup of phenothiazines with antipsychotic action since promethazine and methdilazine, drugs lacking antipsychotic activity, did not have this effect (1, 2, 4). These observations (for review see ref. 4), and the coincidence of "parkinsonian" side effects in patients during therapy with neuroleptic drugs, have led to the speculation that the effects of antipsychotic drugs on dopamine metabolism in the brain might be specifically related to their psychiatric and neurological effects in patients. Until recently, only indirect in vivo methods existed to evaluate the effectiveness of drugs as dopamine-receptor blockers, notably the rate of rise of homovanillic acid, the main metabolite of dopamine, in brain and cerebrospinal fluid. The recent discovery of a dopamine-sensitive adenylate cyclase (EC 4.6.1.1) in homogenates of corpus striatum prepared from rat brain and its similarity or close relationship with the dopamine receptor (5) has prompted the present study. We attempted to learn whether drugs with antipsychotic action would inhibit stimulation of dopamine-sensitive adenylate cyclase and if their clinically ineffective structural analogs would fail to inhibit stimulation by dopamine in vitro. and used without further purification. The drugs were obtained from several sources. * MAethods. Dopamine-sensitive adenylate cyclase was assayed with cell-free homogenates from rat corpus striatum (caudateputamen) obtained from the brains of Sprague-Dawley rats weighing 200-250 g, as described (5). Rats were killed by decapitation, and the striatum was rapidly dissected and homogenized in a glass Elvehjem-type homogenizer with a motor-driven Teflon pestle in 25 volumes (v/w) of a hypotonic medium that contained 2 mM Tris-maleate buffer (pH 7.4) and 2 mM EGTA. To each incubation tube 0.010 ml of the homogenate was added. The standard incubation medium (final volume, 0.05 ml) contained in mM: Tris-maleate buffer (pH 7.3), 80; [a-32P]ATP, 0.5 (6 to 9 X 105 cpm); MgSO4, 2; theophylline, 10; EGTA, 0.4; unlabeled cAMP, 0.15; plus test substances. Reactions were initiated by addition of ATP and conducted for 150 sec in a shaking water bath at 300. The reaction was terminated by placing the tubes in a boiling water bath for 2 min; [8-3H]cAMP (1 X 104 cpm) was added as an internal standard to permit estimation of the recovery of cAMP after column chromatography. cAMP was then isolated by chromatography on neutral aluminum oxide columns (6). Radioactivity was determined by liquid scintillation spectrometry. Recovery of [3H]cAMP was 90-100%. Blank values were obtained by incubation of the complete * Drugs were generously contributed as follows: chlorpromazine-
efficacy, all inhibit stimulation of adenylate cyclase by 40 uM dopamine at micromolar concentrations. Among 14 other structurally related drugs that-are not clinically effective as antipsychotic agents, 12 were almost ineffective while two drugs were moderate inhibitors of dopaminesensitive adenylate cyclase.
Phenothiazines and other structurally analogous drugs with antipsychotic action and neuroleptic drugs of the butyrophenone and diphenylpiperidine classes are reported to enhance 3,4-dihydroxyphenylethylamine (dopamine) turnover in the brain (1) (2) (3) (4) , possibly as a consequence of their blockade of dopamine receptors. This enhancement of dopamine turnover in the basal ganglia by neuroleptic agents has been suggested to be characteristic only for the subgroup of phenothiazines with antipsychotic action since promethazine and methdilazine, drugs lacking antipsychotic activity, did not have this effect (1, 2, 4) . These observations (for review see ref. 4) , and the coincidence of "parkinsonian" side effects in patients during therapy with neuroleptic drugs, have led to the speculation that the effects of antipsychotic drugs on dopamine metabolism in the brain might be specifically related to their psychiatric and neurological effects in patients. Until recently, only indirect in vivo methods existed to evaluate the effectiveness of drugs as dopamine-receptor blockers, notably the rate of rise of homovanillic acid, the main metabolite of dopamine, in brain and cerebrospinal fluid. The recent discovery of a dopamine-sensitive adenylate cyclase (EC 4.6.1.1) in homogenates of corpus striatum prepared from rat brain and its similarity or close relationship with the dopamine receptor (5) has prompted the present study. We attempted to learn whether drugs with antipsychotic action would inhibit stimulation of dopamine-sensitive adenylate cyclase and if their clinically ineffective structural analogs would fail to inhibit stimulation by dopamine in vitro. thioridazine, and trimeprazine were comparable to chlorpromazine as inhibitors of dopamine-stimulated adenylate cyclase. Chlorpromazine and haloperidol had in our experiments similar potency, which is consistent with earlier findings of Kebabian et al. (5), who also studied these two neuroleptic drugs. Chlorprothixene, a thioxanthene, was as potent as fluphenazine (Table 1) . Droperidol, a butyrophenone, was a relatively weak inhibitor of dopamine-stimulated adenylate cyclase, in contrast to haloperidol. Clozapine, a drug reported to be antipsychotic (9) , although lacking neuroleptic activity in animals (10), was a relatively weak inhibitor of dopaminestimulated adenylate cyclase.
We of the exogenous unlabeled cAMP, has been reported to be less than 10% (5) . Moreover, the concentrations of antipsychotic drugs that inhibited dopamine-stimulated adenylate cyclase were generally 100 times lower than those that are required to inhibit cAMP-phosphodiesterase in brain tissue (11) . We studied dopamine-stimulated adenylate cyclase in homogenates of striatal tissue prepared by homogenization in a hypotonic medium to disrupt compartments enclosed by cellular and subcellular membranes. Thus, effects of drugs on amine-uptake mechanisms, which might influence the results with more complex tissue such as brain minces or slices, are unlikely to affect our results, since dopamine uptake does not occur in hypotonic homogenates (12) .
With few exceptions, there is a good correlation between the effects on dopamine-stimulated adenylate cyclase in vitro and the effects of antipsychotic drugs on the turnover of dopamine in the striatum in vivo. Thus, the antipsychotic drugs and potent inhibitors of the response of adenylate cyclase to dopamine (Table 1) , chlorpromazine (1, 2, 4, 13, 14), fluphenazine (13), haloperidol (2, 13), and chlorprothixene (2, 13) , are all reported to increase dopamine turnover in basal ganglia. Trimeprazine in low doses exerts antipruritic effects (15) . It was used in a recent study as nonantipsychotic "control" phenothiazine, and produced a marked increase of dopamine turnover in basal ganglia (4). However, in higher doses, trimeprazine has antipsychotic properties (16) (17) (18) , and it was a potent inhibitor of dopamine-stimulated adenylate cyclase (Table 1) . Conversely, the nonantipsychotic drugs and weak inhibitors of dopamine-stimulated adenylate cyclase (Table 2) , promethazine (1, 2, 4) and methdilazine (4), are reported not to enhance dopamine turnover in vivo. The butyrophenones gave evidence of inhibitory potency far less than their clinical potency or in vivo neuroleptic activity would predict (10, 19) . Droperidol was particularly weak, and was about as potent as thiethylperazine, a drug considered to be "poorly antipsychotic" (Tables 1 and 2) . These results are consistent with the previous report of relatively weak activity of haloperidol in very similar experiments by Kebabian et al. (5) . The results would thus appear to suggest either that the actions in vivo of the butyrophenones are not well represented by our measurements in vitro, or that the behavioral and antipsychotic effects of these agents are not simply dependent on the blockade of dopamine receptors. Many other reasons might be given for this discrepancy, since different classes of drugs might have a different distribution and metabolism in vivo and since dopaminesensitive adenylate cyclase might not completely represent the dopamine receptor or might have different properties in other brain areas such as the limbic system. Further studies of the potency and actions of these agents in vivo and in vitro are clearly indicated. Two other exceptional drugs are clozaover in vivo in the basal ganglia of rabbits, mice, and cats after single doses but not after chronic administration (20) ; there is less effect in rats (14) and none in monkeys (4) . Clozapine increases levels of homovanillic acid in striatal tissue only at high doses (21) . Differences between clozapine or thioridazine and other antipsychotic drugs on extrapyramidal control of movement have also been observed. Clozapine is reported to have antipsychotic properties (9), but is not a neuroleptic drug and does not produce catalepsy in animals (10) . Higher doses of thioridazine are necessary to produce catalepsy in animals when it is compared with other neuroleptic drugs, including other phenothiazines (10, 14) or butyrophenones (10) . Thioridazine is less potent than chlorpromazine in supressing metamphetamine-induced locomotor behavior in rats with unilateral lesions of the anterior portion of the substantia nigra (22) . The relatively weak actions of these two agents upon presumably striatal motor functions in animals appear to correspond with the low incidence of extrapyramidal side effects in patients treated with thioridazine (23) or clozapine (9) . These experimental and clinical observations have been used to argue against the concept that the blockade of dopamine receptors might underly the therapeutic antipsychotic effects of thioridazine (22) and clozapine (10) . However, we find that in homogenates of rat brain striatumn, the antipsychotic drug thioridazine is almost as potent an inhibitor of dopamine-sensitive adenylate cyclase as the antipsychotic neuroleptic drug chlorpromazine, suggesting that both drugs are potent inhibitors of dopamine receptors (Table 1) . While clozapine was weaker in its antagonism of the effect of dopanline than thioridazine, it was active (Table 1) . Thus, other pharmacological effects. of thioridazine and clozapine unrelated to their actions on the dopamine receptors in the striatum might be responsible for antipsychotic activity, together with the relative lack of effects on the extrapyramidal system. One difference between neuroleptic drugs and clozapine is the strong anticholinergic potency of clozapine (10) . While thioridazine has been reported to have somewhat stronger anticholinergic potency than chlorpromazine (24) (25) (26) , as estimated in several preparations of peripheral tissues, the potency of these agents against central muscarinic receptors is apparently unknown.
In summary, the present results have shown that antipsychotic and neuroleptic drugs are potent inhibitors of dopamine-sensitive adenylate cyclase, suggesting that blockade of dopamine receptors in the cehtral nervous system might be involved in the mechanism of action of antipsychotic drugs. However, there appears to be a discrepancy between the potency of the butyrophenones in vivo and their action on dopamine-sensitive adenylate cyclase in vitro. 
